|Bid||8.84 x 21500|
|Ask||8.85 x 800|
|Day's Range||8.58 - 8.88|
|52 Week Range||7.96 - 25.96|
|Beta (3Y Monthly)||2.49|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.73|
Tel Aviv-based cannabis company Syqe Medical has introduced the world's first pharmaceutical-grade metered-dose cannabis inhaler in Israel. The Syqe Inhaler has received the world's first ever regulatory approval from the Israeli Ministry of Health as a medical device combined with cannabis and will be available for purchase by licensed patients in Israel. Breakthrough Drug Delivery […]The post Syqe Medical Unveils World's 1st Pharma-Grade Metered-Dose Cannabis Inhaler appeared first on Market Exclusive.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Teva Pharmaceutical Industries Ltd. (“Teva” or “the Company”) (NYSE: TEVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between August 4, 2017 and May 10, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before August 20, 2019.
NEW YORK, NY / ACCESSWIRE / June 25, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Teva Pharmaceutical Industries Ltd. ("Teva" or the "Company") (TEVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Teva American Depositary Shares ("ADS") between August 4, 2017 and May 10, 2019, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
A judge in Oklahoma signed off on the state’s $85 million settlement with Israeli-owned Teva Pharmaceuticals on Monday following a squabble between the attorney general, Legislature and governor over how the deal was structured.
The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma came after the state's attorney general, governor and top lawmakers resolved a dispute over how the money should be deposited and spent. Oklahoma Attorney General Mike Hunter struck an initial settlement with Teva on May 26, just days before the Israel-based drugmaker was set to face trial alongside Johnson & Johnson, which is continuing to fight the case. The settlement resolved claims that Teva and other drugmakers helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities.
Saxena White P.A. has filed a securities fraud class action lawsuit in the United States District Court for the Eastern District of Pennsylvania against Teva Pharmaceutical Industries Ltd. (“Teva”) (TEVA) on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019, inclusive (the “Class Period”). If you purchased Teva ADS during the Class Period and wish to apply to be lead plaintiff, a motion on your behalf must be filed with the Court by no later than August 20, 2019.
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.12 in the latest trading session, marking a -0.73% move from the prior day.
(Bloomberg) -- An Oklahoma case, the first of more than 1,600 lawsuits filed by U.S. state and local governments against opioid makers to go to trial, could serve as a key benchmark for governments hoping to recoup costs associated with the public health crisis.However, verdicts and legal settlements resulting from the litigation are likely to be smaller than the 1998 global settlement with tobacco companies and won’t significantly affect government budgets, according to Fitch Ratings.The tobacco settlement with 46 states compensated them with more than $200 billion for decades of tobacco-related health-care costs, but wasn’t enough to alter state and local government credit quality, according to Fitch. The opioid epidemic has taken place over a shorter time span, and hasn’t resulted in as many deaths, according to Marcy Block, a Fitch analyst.“It’s severe, but it’s less if you think about the amount of deaths through tobacco usage,” Block said.Ten TimesMore than 47,000 Americans died from opioid overdoses in 2017, including heroin and fentanyl, a synthetic opioid, according to the National Institute on Drug Abuse. Cigarette smoking is responsible for ten times as many deaths annually, according to the Centers for Disease Control and Prevention.Oklahoma sued Johnson & Johnson, Purdue Pharma LP and Teva Pharmaceutical Industries Ltd. in 2017, alleging the companies deceived the public by overstating the benefits of their drugs while downplaying the risk of addiction. Teva in May agreed to pay $85 million to resolve the suit. Purdue Pharma, the maker of OxyContin, agreed in March to pay $270 million.Read more about how opioid makers are getting squeezed as cities try to form a negotiating groupThe opioid litigation could cost the pharmaceutical industry between $5 billion and $50 billion, based on the 1998 tobacco deal and costs of the abuse epidemic, according to Bloomberg Intelligence analyst Holly Froum. Oklahoma is seeking at least $10 billion in damages and penalties for current and future outlays from Johnson & Johnson.“The depth of evidence against the opioid manufacturers, including any potential evidence of fraudulent marketing, will be a key determinant not only of how this case is decided, but the thousands of additional cases against the industry, “ wrote Rachel Barkley, a senior vice president at Loop Capital Markets earlier this month.“Additionally, the size of any settlement would likely serve as a benchmark in future cases,” she said.Securtitized ProceedsStates and local governments issued tens of billions of dollars in muni bonds backed by the tobacco settlement and some used that money to plug budget gaps. The securities are repaid with the money they receive each year from cigarette companies under the settlement. The amount of the payments is based on annual cigarette shipments. There are currently $85 billion of tobacco bonds outstanding, including debt issued to refinance previously issued securities.At least 42 states and more than 1,900 municipalities have sued opioid manufactures and distributors, blaming them for creating a national public-health crisis and demanding billions of dollars in damages.A U.S. federal judge in Cleveland is overseeing opioid litigation brought by U.S. cities and counties and has set two trials for October. The scope of the litigation could result in a global settlement that mimics the resolution to the tobacco cases in the 1990s.The CDC estimates that the total “economic burden” of prescription opioid misuse alone in the U.S. is $78.5 billion a year, including the costs of health care, lost productivity, addiction treatment and criminal justice involvement.Factoring the economic value of lives lost, the White House’s Council of Economic Advisers estimated the costs of the epidemic in 2015 totaled $504 billion.Related: States Are Suing Opioid Makers But Their Pensions Embrace ThemTo contact the reporter on this story: Martin Z. Braun in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: James Crombie at email@example.com, Michael B. Marois, Shannon D. HarringtonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Tracleer®1 (bosentan) tablets, 62.5 mg and 125 mg, in the U.S. Bosentan Tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) in adults to improve exercise ability and to decrease worsening of the condition. PAH is high blood pressure in the blood vessels of the lungs.
Pfizer stock has fallen 2% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Citi Research analyst Liav Abraham maintained her Buy rating on Teva, but dropped her target price to $13 from $23, and wrote that the company was off Citi’s Focus List.
Ongoing litigation surrounding the opioid epidemic will be a yearslong overhang for several pharmaceutical companies like Teva Pharmaceutical, Mylan and Endo, an analyst said Thursday.
Wednesday's 0.2% setback for the S&P 500 still wasn't enough to push it past the point of no return. But, anything remains possible at this point … good or bad. More than anything, traders are losing interest.Source: Allan Ajifo via Wikimedia (Modified)Teva Pharmaceutical (NYSE:TEVA) was a proverbial problem child, off more than 4% after a judge rejected its initial settlement offer to end an opioid liability case against the company. Chesapeake Energy (NYSE:CHK) was the bigger overall drag, falling more than 7%, mostly driven by industry pricing weakness. General Electric (NYSE:GE) helped keep the weakness to a minimum, up 1.5% as investors increasingly buy into the turnaround story. * 7 High-Quality Cheap Stocks to Buy With $10 None are great picks headed into Thursday's trading though. Rather, it's the stock charts of Philip Morris International (NYSE:PM), Twitter (NYSE:TWTR) and H & R Block (NYSE:HRB) that merit the closer looks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips H & R Block (HRB)Shares of H & R Block are, in simplest terms, at a crossroads.The fact that HRB was able to recover and rebound after being on the verge of a pretty significant selloff (as recently as March) confirmed there's a rather significant floor around $23.65, plotted in blue on both stock charts. However, this week's action also confirms there's a major ceiling that stands in the way of higher highs. Although the stock could still fall on either side of the fence, with two years' worth of consolidation ready to be unleashed, the possible breakout thrust is worth a closer look. Click to Enlarge * The ceiling in question is, of course, the $29.20 level marked in red on both stock charts. That's around where H & R Block stock peaked several times since late 2017. * Although none of the other attempts to hurdle $29.20 have been effective, this one differs in that the last couple days have made big gains on big volume. * Perhaps the most bullish argument here isn't what is, but what isn't. The weekly chart's RSI indicator hasn't crept into overbought territory yet, leaving room for more upside before the profit-takers push back. Philip Morris (PM)With nothing more than a passing glance at Philip Morris, it looks as if it has averted trouble. And, perhaps it has. The weakness seen late last month has been quelled, with a technical support level taking shape around $76.70.This may only be a short pause before the selloff resumes again, however. One more misstep could push PM shares over that cliff's edge. * 10 Smart Dividend Stocks for the Rest of the Year Click to Enlarge * The way the highs and lows over the course of the past week and a half have made a pretty well-defined box shape is telling in itself. It could be considered a bearish continuation pattern that lets the sellers regroup. * The floor at $76.70 is more meaningful than the past few days would suggest. That same level was a key floor a trio of times in 2018, making it a more important support area now. * Still, until that floor actually fails to keep Philip Morris stock propped up, there's still a chance at a rebound. Twitter (TWTR)Several times earlier this year Twitter was featured as a budding bullish candidate. Although choppy, the fact that the buyers were repeatedly making an attempt to reclaim ground lost in the middle of last year was encouraging. The breakout move finally took shape in April, though in the worst possible way. That is, a huge gap was left behind; traders generally don't like to leave gaps unfilled.Sure enough, that gap was filled in the meantime, with last month's weakness. The spot with which the bounceback has taken shape, however, suggests a whole new trading range has been established that will serve as a Launchpad for the move to the next higher level. Click to Enlarge * All it took was a kiss of the gray 100-day moving average line in early June (highlighted) to close the gap left with April's surge. * This week so far, the purple 50-day moving average line and the blue 20-day moving average line have acted as a technical floor, holding TWTR above a key technical ceiling near $37.20, plotted in red. * The next level to watch is $42.14, where the upper boundary of July's bearish gap is found. * It's more readily evident on the weekly chart, but with the recent move higher, the old trading range between $35.80 and $26.25 has been left in the rearview mirror.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Quality Cheap Stocks to Buy With $10 * 7 U.S. Stocks to Buy With Limited Trade War Exposure * 6 Growth Stocks That Could Be the Next Big Thing Compare Brokers The post 3 Big Stock Charts for Thursday: H & R Block, Twitter and Philip Morris appeared first on InvestorPlace.
Teva Pharmaceutical skidded to a nearly two-decade low Wednesday amid confusion over its $85 million payment to Oklahoma to settle an ongoing opioid abuse case. J&J remains a defendant.
Teva shares briefly reached fresh lows after an Oklahoma judge declined the company's settlement offer and requested more information.
Short sellers are taking a growing interest in the specialty pharmaceutical sector as litigation concerns swirl around Teva and Allergan.
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Has Roku Stock Price Hit Its Peak? * Will Qualcomm (QCOM) Stock Win Again? Canaccord Remains Bullish * Canopy Growth (CGC) Continues to Struggle to Find Its Identity * Apple & Google’s Vision of the Future Contrasted by Developer Resources
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter. One of these stocks was Teva Pharmaceutical Industries Limited (NYSE:TEVA). Teva Pharmaceutical Industries Limited (NYSE:TEVA) […]
Conventional wisdom says that insiders and 10-percent owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. MGM Resorts International (NYSE: MGM) saw a director making indirect share purchases this past week.
The case, which is premised on a unproven legal theory, could impact the course of future opioid litigation.